Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases.

IF 2.5 Q2 GASTROENTEROLOGY & HEPATOLOGY World Journal of Hepatology Pub Date : 2024-09-27 DOI:10.4254/wjh.v16.i9.1308

Marwan S M Al-Nimer

{"title":"Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases.","authors":"Marwan S M Al-Nimer","doi":"10.4254/wjh.v16.i9.1308","DOIUrl":null,"url":null,"abstract":"The albumin-bilirubin (ALBI) score is a useful prognostic marker that predicts mortality in patients suffering from terminal diseases. Recently, it has been reported that ALBI score is a predictor of non-malignant liver diseases. The cutoff point of the ALBI score that distinguishes hepatocellular carcinoma from non-malignant liver disease is still not identified. Therefore, the ALBI score is a sensitive rather than a specific predictor of the poor outcomes of liver diseases. There are many hematological indices and ratios that are utilized as prognostic biomarkers. Among these biomarkers are the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), and platelet-hemoglobin ratio (PHR), which are useful discriminating prognostic biomarkers for liver diseases, e.g., hepatocellular carcinoma, hepatitis, liver fibrosis, etc. There is evidence that PLR and PHR are prognostic biomarkers that predict the poor outcomes of diseases. Therefore, concomitant measurements of ALBI score and PHR or ALBI score and PLR will improve the predictive value that can differentiate hepatocellular carcinoma from non-malignant diseases.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438590/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4254/wjh.v16.i9.1308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The albumin-bilirubin (ALBI) score is a useful prognostic marker that predicts mortality in patients suffering from terminal diseases. Recently, it has been reported that ALBI score is a predictor of non-malignant liver diseases. The cutoff point of the ALBI score that distinguishes hepatocellular carcinoma from non-malignant liver disease is still not identified. Therefore, the ALBI score is a sensitive rather than a specific predictor of the poor outcomes of liver diseases. There are many hematological indices and ratios that are utilized as prognostic biomarkers. Among these biomarkers are the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), and platelet-hemoglobin ratio (PHR), which are useful discriminating prognostic biomarkers for liver diseases, e.g., hepatocellular carcinoma, hepatitis, liver fibrosis, etc. There is evidence that PLR and PHR are prognostic biomarkers that predict the poor outcomes of diseases. Therefore, concomitant measurements of ALBI score and PHR or ALBI score and PLR will improve the predictive value that can differentiate hepatocellular carcinoma from non-malignant diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

同时测定血液学指标支持白蛋白-胆红素评分在非恶性肝病中的应用。

白蛋白-胆红素（ALBI）评分是一种有用的预后指标，可预测绝症患者的死亡率。最近有报道称，ALBI 评分可预测非恶性肝病。区分肝细胞癌与非恶性肝病的 ALBI 评分临界点仍未确定。因此，ALBI 评分是预测肝病不良后果的敏感指标，而非特异指标。有许多血液学指数和比率被用作预后生物标志物。在这些生物标志物中，中性粒细胞与淋巴细胞比率、血小板与淋巴细胞比率（PLR）和血小板与血红蛋白比率（PHR）是肝脏疾病（如肝细胞癌、肝炎、肝纤维化等）的有效判别预后的生物标志物。有证据表明，PLR 和 PHR 是预测疾病不良后果的预后生物标志物。因此，同时测量 ALBI 评分和 PHR 或 ALBI 评分和 PLR 将提高预测价值，从而区分肝细胞癌和非恶性疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊